Presentations
December 2021
A Phase 1 Dose Escalation Study of IGM-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies
63rd American Society of Hematology (ASH) Annual Meeting and Exposition – December 11-14, 2021 – Session: 623. Mantle Cell, Follicular, and Other B-Cell Lymphomas
November 2021
IGM-7354 is an anti-PD-L1 IgM antibody and IL-15 cytokine fusion that enhances NK and CD8+ T cell proliferation and tumor cytotoxicity plus potently reverses T cell exhaustion
The Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting & Pre-Conference Programs – November 12-14, 2021
November 2021
Multimeric IgM Antibodies Targeting DR5 are Potent and Rapid Inducers of Tumor Cell Apoptosis In Vitro and In Vivo
PEGS Europe – November 4, 2021
April 2021
Mechanistic evaluation of anti-DR5 IgM antibody IGM-8444 with potent tumor cytotoxicity, without in vitro hepatotoxicity
American Association for Cancer Research (AACR) Annual Meeting 2021, Virtual – April 10-15, 2021 – Session: Therapeutic Mechanisms of Novel Anticancer Agent